Provention Bio, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: Oldwick NJ United States (2016)
Status: Acquired by Sanofi-Aventis

Organization Overview

First Clinical Trial
2018
NCT03849599
First Marketed Drug
2022
teplizumab (Tzield)
First NDA Approval
2022
teplizumab (Tzield)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Provention Bio | Provention Bio, Inc. | PROVENTION BIO INC

Active Ingredients

Marketed Drugs (1)

teplizumab (Tzield) (2022 NDA)

Drugs in Phase 4 Trials (1)

teplizumab (Tzield) (3 trials)

Drugs in Phase 2 Trials (3)

prv-015 (1 trial)

prv-3279 (2 trials)

prv-6527 (1 trial)

Drugs in Phase 1 Trials (2)

prv-101 (1 trial)

prv-300 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Coxsackievirus Infections (Phase 1)

Crohn Disease (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Ulcer (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 6